Myasthenia gravis (MG) is an antibody-mediated neuromuscular disease affecting the neuromuscular junction. In most cases, autoantibodies can be detected in the sera of MG patients, thus aiding in diagnosis and allowing for early screening. However, there is a small proportion of patients who have no detectable auto-antibodies, a condition termed "seronegative MG" (SnMG). Several factors contribute to this, including laboratory test inaccuracies, decreased antibody production, immunosuppressive therapy, immunodeficiencies, antigen depletion, and immune-senescence. The diagnosis of SnMG is more challenging and is based on clinical features and neurophysiological tests. The early identification of these patients is needed in order to ensure early treatment and prevent complications. This narrative review aims to examine the latest updates on SnMG, defining the clinical characteristics of affected patients, diagnostic methods, management, and therapeutic scenarios.

Vinciguerra, C., Bevilacqua, L., Lupica, A., Ginanneschi, F., Piscosquito, G., Rini, N., et al. (2023). Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows. BRAIN SCIENCES, 13(9), 1-13 [10.3390/brainsci13091286].

Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows

Lupica, Antonino;Rini, Nicasio;Barone, Paolo;Brighina, Filippo;Di Stefano, Vincenzo
2023-09-05

Abstract

Myasthenia gravis (MG) is an antibody-mediated neuromuscular disease affecting the neuromuscular junction. In most cases, autoantibodies can be detected in the sera of MG patients, thus aiding in diagnosis and allowing for early screening. However, there is a small proportion of patients who have no detectable auto-antibodies, a condition termed "seronegative MG" (SnMG). Several factors contribute to this, including laboratory test inaccuracies, decreased antibody production, immunosuppressive therapy, immunodeficiencies, antigen depletion, and immune-senescence. The diagnosis of SnMG is more challenging and is based on clinical features and neurophysiological tests. The early identification of these patients is needed in order to ensure early treatment and prevent complications. This narrative review aims to examine the latest updates on SnMG, defining the clinical characteristics of affected patients, diagnostic methods, management, and therapeutic scenarios.
5-set-2023
Vinciguerra, C., Bevilacqua, L., Lupica, A., Ginanneschi, F., Piscosquito, G., Rini, N., et al. (2023). Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows. BRAIN SCIENCES, 13(9), 1-13 [10.3390/brainsci13091286].
File in questo prodotto:
File Dimensione Formato  
brainsci-13-01286.pdf

accesso aperto

Descrizione: review
Tipologia: Versione Editoriale
Dimensione 600.77 kB
Formato Adobe PDF
600.77 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/635473
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact